CURRENT
ISSUE1572
May 20, 2019
The FDA has approved Inbrija (Acorda), an orally
inhaled dry-powder formulation of levodopa, for
intermittent treatment of "off" episodes in patients
with Parkinson's disease (PD) being treated with
carbidopa/levodopa (Sinemet, and others). read more...
More from issue 1572
Coming Soon
Drugs for Psoriasis
Romosozumab (Evenity) for Postmenopausal Osteoporosis
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
Risankizumab (Skyrizi) for Psoriasis
Tafenoquine (Arakoda and Krintafel) for Malaria
Recommend to Your Library
We're Essential. Begin your free trial
Previous Issues
May 6, 2019 (1571)
- Insulins for Type 2 Diabetes
- Brexanolone (Zulresso) for Postpartum Depression
- Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
- In Brief: Tegaserod (Zelnorm) Returns
- Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
April 22, 2019 (1570)
- OTC Drugs for Seasonal Allergies
- Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections
- Ozenoxacin 1% Cream (Xepi) for Impetigo
April 8, 2019 (1569)
- Drugs for Chronic Heart Failure
- Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression
- Expanded Table: Some Drugs for HFrEF (online only)
March 25, 2019 (1568)
- ZTlido - A New Lidocaine Patch for Postherpetic Neuralgia
- Sarecycline (Seysara) - Another Oral Tetracycline for Acne
- Sulfonamide Cross-Reactivity
- Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria
- In Brief: Erenumab (Aimovig) Hypersensitivity
March 11, 2019 (1567)
